Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
about
Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureAntiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia.Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialCD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapyShould viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settingsPerformance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.HIV-1 low copy viral sequencing-A prototype assay.Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-la
P2860
Q33584656-02AF2239-0880-4688-A55E-10AFF0C523E2Q33775397-BE39CC82-E038-4BEC-A003-0C13C1FA3E70Q33798584-E4C40E3F-A5E9-4201-88B9-12830CF082D2Q33934935-DFA8BDFE-E840-4B01-A6DD-7AE03C235313Q34289476-0AD764EB-6E35-4E99-9E31-35FBD7F76A03Q34539993-5CE9568C-B221-4516-9478-E6286EDDD786Q34781706-7802ED19-6BD1-47EE-A319-5A221AA96624Q35408114-01144B4C-21D1-4C3E-8EF7-65FBE877C968Q35682519-22679CDE-5848-4FD0-8FAA-AEADA43DC0C8Q35698144-AF98025D-83AB-4723-953C-A8F6C31784CDQ35885190-81D45B42-9F75-4F28-90E3-A89C7773003BQ36784163-A3D8AFE7-53DF-4005-B1D5-9339C234D1E0Q37116750-6BAC0A00-1FA6-4091-89FF-60A3F97EC57DQ37668850-EBED37DC-5EF9-49EA-B5CB-2E45444FF29FQ38675771-4DDE0206-14DE-4ECB-A681-45DF9AD8CE01Q40111552-C142AC49-7327-4E94-92B5-CE92AF7A3F1EQ40783234-26B868BD-2FDE-4BB7-A6A0-E894DAC79A4BQ49344179-74F7B045-8269-4B2C-93E6-BB27283EB82C
P2860
Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Prevalence and significance of ...... detectable low-level viremia.
@ast
Prevalence and significance of ...... detectable low-level viremia.
@en
type
label
Prevalence and significance of ...... detectable low-level viremia.
@ast
Prevalence and significance of ...... detectable low-level viremia.
@en
prefLabel
Prevalence and significance of ...... detectable low-level viremia.
@ast
Prevalence and significance of ...... detectable low-level viremia.
@en
P2093
P2860
P356
P1476
Prevalence and significance of ...... detectable low-level viremia.
@en
P2093
Daniel R Kuritzkes
Hiroyu Hatano
Jeffrey N Martin
Jonathan Z Li
Sebastien Gallien
P2860
P304
P356
10.1128/AAC.01217-12
P407
P577
2012-08-13T00:00:00Z